Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Some treatments for rheumatoid arthritis could increase cancer risk. One reason is because some cells in our immune system ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

It’s the kind of policy that sounds tough, fixes nothing, and risks triggering a chain reaction — one that circles straight ...